Thus, aberrantly increased DUX4 expression is the primary mediator of FSHD pathophysiology, the DUX4-fl mRNA and protein are prime FSHD therapeutic targets, and animal models for FSHD should be based on expression of DUX4. Here, DUX4 is linked to facioscapulohumeral muscular dystrophy.